Study design of subcutaneous and intravenous single dosing of IL-10 and αIL-10 in BALB/c or CD-1 female mice
| Protein or Antibody | Route | Dose | Observation Period | Mice | PK Analysis | TD Analysis |
|---|---|---|---|---|---|---|
| days | ||||||
| mIL-10 | i.v. | 3.0 | 1 | BALB/c | ECL | |
| PEG-mIL-10 | i.v. | 3.0 | 2 | BALB/c | ELISA | |
| Native and 649-labeled mIL-10 | s.c. | 3.0 | 1.25 | BALB/c | ECL | FELA |
| Native and 649-labeled PEG-mIL-10 | s.c. | 3.0 | 2 | BALB/c | ELISA | FELA |
| Native and 649-labeled hαhIL-10 12G8 | i.v. | 3.0 | 28 | CD-1 | ELISA | FELA |
| 649-hαhIL-10 12G8 | i.v. | 3.0 | 28 | CD-1 | FELA | FELA |
| 649-hIL-10 | i.v. | 3.0 | 3 | CD-1 | FELA | FELA |
| 649-hIL-10 + hαhIL-10 12G8 | i.v. | L: 3.0; mAb: 25.0 | 3 | CD-1 | FELA | FELA |
| 649-hIL-10 | s.c. | 20.0 | 2 | BALB/c | FELA | FELA |
| 649-hIL-10 + mαmIL-10 11D8 | L: s.c.; mAb: i.v. | L: 20.0; mAb: 60.0 | 4 | BALB/c | FELA | FELA |
| 649-hIL-10 + 549-hαhIL-10 12G8 | i.v. | L: 5; mAb: 25.0 | 0.04 | CD-1 | FELAa |
ECL, electrochemiluminescence assay; L, ligand; mAB, monoclonal antibody.
↵a In vivo experiment was only performed for fluorescence scanning analysis.